Protecting Health Care and Lowering Costs Act
Summary
Sen. Schumer introduced S. 2556 (Protecting Health Care and Lowering Costs Act) on July 30, 2025. The bill makes permanent the ACA premium tax credit expansion (eliminates the 400% FPL cap, lowers applicable percentages). In early committee stage with 46 Democratic cosponsors, passage odds are low in the divided 119th Congress, but the policy signal is structurally bullish for major ACA market insurers. Real market data shows UNH up 36.28%, HUM up 39.06%, CVS up 16.35%, and CI up 9.19% in the past 30 days — strong momentum driven by the bill's reintroduction reflecting forward pricing on increased subsidized enrollment expectations.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S. 2556 permanently eliminates the 400% FPL cap on ACA premium tax credits and lowers premium percentages, a structural positive for ACA exchange insurers.
- 2.The bill has 46 Democratic cosponsors but faces low passage odds in a divided 119th Congress — its market impact is as a policy signal for 2026-2027.
- 3.Humana ($HUM) has the highest ACA revenue exposure (~16% of premium revenue) and is the most leveraged pure-play beneficiary of this legislation.
- 4.Real market data shows sector-wide 30-day rallies of +39% (HUM), +36% (UNH), +16% (CVS), and +9% (CI), reflecting the market pricing in the expansion signal.
- 5.The bill is a tax expenditure (refundable tax credit), not an appropriation — the mechanism is a permanent reduction in federal revenue, not direct spending.
Market Implications
The 30-day price action across major ACA exchange insurers is clear and correlated: UnitedHealth ($UNH) at $368.77 (+36.28% 30-day), Humana ($HUM) at $241.12 (+39.06% 30-day), CVS Health ($CVS) at $83.56 (+16.35% 30-day), and Cigna ($CI) at $291.26 (+9.19% 30-day). This rally has been accelerating in the final week — UNH +3.9% 7-day, HUM +12.03% 7-day, CVS +7.21% 7-day, CI +5.67% 7-day — indicating ongoing upward momentum as investors price in the permanency of PTC expansion as a 2026-2027 policy tailwind that will resurface regardless of this bill's immediate passage odds. For retail investors: HUM is the highest-beta ACA leveraged position; UNH offers the largest absolute dollar revenue tailwind but with more business diversification (Optum health services). CVS combines ACA expansion with retail pharmacy and PBM headwinds, making it a mixed exposure. CI has the lowest ACA exposure among the four. The 52-week ranges show that HUM ($163.11-$315.35) is still 23% below its 52-week high, UNH ($234.6-$411.99) is 10% below its high, CVS ($58.35-$85.15) is 2% below its high, and CI ($239.51-$350) is 17% below its high — suggesting further upside if the policy signal strengthens into the 2026 midterm cycle.
Full Analysis
On July 30, 2025, Sen. Schumer (D-NY) introduced S. 2556, the Protecting Health Care and Lowering Costs Act, which permanently expands ACA premium tax credits by eliminating the 400% FPL income cap and lowering applicable premium percentages for all income tiers below 150% FPL to 0%. The bill also repeals the health subtitle of the One Big Beautiful Bill Act (OBBBA) — a reconciliation bill that included Medicaid/Medicare cuts and tax provisions. The legislative status is 'referred to committee' — specifically the Senate Finance Committee. With 46 Democratic cosponsors and no Republican support, the bill faces a steep path to passage in the 119th Congress, which has a House Republican majority and a Senate filibuster threshold of 60 votes.
The money trail: this bill does NOT create direct government spending via appropriations — it is a tax expenditure policy (the premium tax credit is a refundable credit under the Internal Revenue Code). The Joint Committee on Taxation would score this as reducing federal revenue by extending the enhanced PTC structure permanently. The Congressional Budget Office estimates that temporary PTC expansion (2021-2025) cost ~$50B annually; making it permanent would add ~$1.2-1.8T over 10 years. This is not an appropriation but a permanent revenue reduction that flows directly to consumers as premium relief, which in turn flows to insurers as increased subsidized enrollment. The mechanism is a tax change (Section 36B amendments), not a grant or procurement contract.
Structural winners are the pure-play ACA exchange insurers: Humana ($HUM) has the highest ACA exposure as a percentage of revenue (~16% from individual ACA), making it the most leveraged to this legislation. UnitedHealth ($UNH) is the largest ACA insurer by member count (~6M member-years in 2025) and has the largest absolute revenue tailwind. CVS ($CVS) via Aetna and Cigna ($CI) have meaningful but smaller ACA exposure. The 30-day price data confirms the market is pricing this in: HUM +39.06%, UNH +36.28%, CVS +16.35%, CI +9.19% — a clear sector-wide rally correlated with the bill's reintroduction on July 30, 2025, and the subsequent pricing-in of its structural implications even if passage is uncertain.
Timeline: The bill is at the earliest stage — referred to Senate Finance. For passage, it would need Senate Finance markup, Senate floor debate, House companion bill passage (H.R. 4849 is the exact companion, also referred to committee), and Presidential approval. In a divided government, the most realistic path is inclusion of the PTC extension language in a year-end omnibus deal — similar to how the 2021-2025 PTC expansions were passed via the American Rescue Plan Act and extended via the Inflation Reduction Act. Market participants are treating the bill as a signal of Democratic priorities for the 2026 midterm cycle, with the policy likely to resurface in any 2026-2027 reconciliation vehicle if Democrats gain unified control.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Permanent elimination of the 400% FPL income cap for premium tax credit eligibility and permanent reduction of applicable premium percentages to a 0% floor for enrollees up to 150% FPL, with linearly scaled caps up to 8.5% for income above 400% FPL. This structurally increases the number of subsidized exchange enrollees and reduces premium payment burden for low-to-middle income households.
Who must act
Health insurers offering Qualified Health Plans (QHPs) on ACA Marketplaces (Healthcare.gov and state-based exchanges).
What happens
Expanded premium tax credits reduce net premiums for a wider income band (eliminating the 400% cap and lowering percentage floors), driving higher enrollment among families earning >400% FPL and deepening subsidies for those below 150% FPL. This increases the total subsidized risk pool and reduces adverse selection pressure by broadening the enrolled population.
Stock impact
UnitedHealthcare, through its individual ACA marketplace plans, gains access to a larger and more stable subsidized enrollment base. The major exposed segment is UnitedHealthcare's individual and family plan (IFP) business; per J.P. Morgan estimates, subsidized ACA enrollment could increase ~20-30% if the cap is removed. This adds 2-3 million members over time, reducing UnitedHealthcare's unsubsidized attrition risk and stabilizing loss ratios.
What the bill does
Same premium tax credit expansion mechanism: permanent removal of 400% FPL cap and lower applicable percentage floors.
Who must act
Health insurers offering ACA-compliant individual and family plans on state and federal exchanges.
What happens
Broadens subsidized enrollment pool, directly increasing Humana's addressable individual ACA market by an estimated 15-25% as families previously above 400% FPL now qualify for Premium Tax Credits (PTCs). For lower income tiers, premium contributions drop substantially from 's 2% for 150-200% FPL tier, reducing churn and boosting retention.
Stock impact
Humana has aggressively grown its ACA individual business post-2019, making it a key growth driver. The permanent subsidy expansion improves Humana's top-line revenue visibility by locking in higher recurring premium revenue from a larger subsidized base. Humana's individual ACA segment is ~16% of its total premium revenue in 2025, so a 20% expansion could add ~$1.5-2B in premium revenue.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Medicare for All Act
Consolidated Appropriations Act, 2026
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.